Retatrutide, by Soma Pharmaceuticals , is attracting increasing attention as a novel method for obesity control . This innovative compound combines the mechanism of a GLP-1 receptor activator and a GIP receptor activator , intended to effectively promote metabolic improvements but also address associated metabolic factors. Preliminary patient data